{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:12:19Z","timestamp":1795093939889,"version":"4.10.2"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.euroneuro.2013.05.011","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T06:01:19Z","timestamp":1375768879000},"page":"1391-1400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["The cardiovascular safety profile of escitalopram"],"prefix":"10.1016","volume":"23","author":[{"given":"Michael E.","family":"Thase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Reines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney H.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.05.011_bib1","unstructured":"Alexopoulos, G.S., Gordon, J., Zhang, D. 2004. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 29(suppl), S87. See also \u3008http:\/\/www.forestclinicaltrials.com\/CTR\/CTRController\/CTRViewPdf?_file_id=scsr\/SCSR_SCT-MD-27_final.pdf\u3009 (accessed September, 2012)."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib2","first-page":"39","article-title":"Comparative efficacy of escitalopram in the treatment of major depressive disorder","volume":"7","author":"Ali","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2013.05.011_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","author":"Bose","year":"2008","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JGP.0b013e3181591c09","article-title":"Escitalopram in the acute treatment of depressed patients aged 60 years or older","volume":"16","author":"Bose","year":"2008","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v63n0410","article-title":"Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients","volume":"63","author":"Burke","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1471-4159.2004.02835.x","article-title":"Characterization of an allosteric citalopram-binding site at the serotonin transporter","volume":"92","author":"Chen","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.euroneuro.2004.08.008","article-title":"The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors","volume":"15","author":"Chen","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib11","unstructured":"Forest Pharmaceuticals, Inc, 2011. Evaluation of the effects of sequential multiple-dose regimens of escitalopram on cardiac repolarization in healthy subjects. Available from: \u3008http:\/\/www.forestclinicaltrials.com\/CTR\/CTRController\/CTRViewPdf?_file_id=scsr\/SCSR_SCT-PK-21_final.pdf\u3009 (accessed September, 2012)."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0960327107078666","article-title":"Escitalopram ingestions reported to Texas poison control centers, 2002\u20132005","volume":"26","author":"Forrester","year":"2007","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2004.11.011","article-title":"Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials","volume":"87","author":"Goodman","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annemergmed.2009.04.016","article-title":"Clinical and ECG effects of escitalopram overdose","volume":"54","author":"Gorp","year":"2009","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0b013e3182677041","article-title":"Cardiovascular safety of 1-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome","volume":"60","author":"Hanash","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpsychores.2011.07.001","article-title":"Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD)","volume":"72","author":"Hansen","year":"2012","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib100","doi-asserted-by":"crossref","unstructured":"Hayes, B.D., Klein-Schwartz, W., Clark, R.F., Muller, A.A., Miloradovich, J.E., 2010. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J. Emerg. Med. 39, 44\u201348.","DOI":"10.1016\/j.jemermed.2008.06.030"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib17","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/00019442-200510000-00008","article-title":"Escitalopram in the treatment of depressed elderly patients","volume":"13","author":"Kasper","year":"2005","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/bjp.186.3.222","article-title":"Escitalopram in the treatment of social anxiety disorder. Randomised, placebo-controlled, flexible-dosage study","volume":"186","author":"Kasper","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/PSY.0b013e3181b8bb7a","article-title":"Autonomy of autonomic dysfunction in major depression","volume":"71","author":"Koschke","year":"2009","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","article-title":"Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study","volume":"19","author":"Lader","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004850-200307000-00003","article-title":"Escitalopram (10-20mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"18","author":"Lepola","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jemermed.2005.04.013","article-title":"Outcomes after supratherapeutic escitalopram ingestions","volume":"30","author":"LoVecchio","year":"2006","journal-title":"J. Emergency Med."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib23","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.ehj.2003.09.003","article-title":"Depressive symptoms and the risk of sudden cardiac death among the elderly","volume":"24","author":"Luukinen","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib24","unstructured":"Ninan, P.T., Ventura, D., Wang, J., 2003. Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the Congress of the American Psychiatric Association, May 17-22, San Francisco, CA. See also \u3008http:\/\/www.forestclinicaltrials.com\/CTR\/CTRController\/CTRViewPdf?_file_id=scsr\/SCSR_SCT-MD-26_final.pdf\u3009. (accessed September, 2012)."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib25","doi-asserted-by":"crossref","unstructured":"Rapaport, M.H., Bos, A., Zheng, H. 2004. Escitalopram continuation treatment prevents relapse of depressive episodes. J. Clin. Psychiatry65, 44\u201349. See also : \u3008http:\/\/www.forestclinicaltrials.com\/CTR\/CTRController\/CTRViewPdf?_file_id=scsr\/SCSR_SCT-MD-02_final.pdf\u3009 (accessed September, 2012).","DOI":"10.4088\/JCP.v65n0107"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.biopsycho.2005.08.010","article-title":"Cardiac vagal control in depression: a critical analysis","volume":"74","author":"Rottenberg","year":"2007","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1742-7843.2006.pto_295.x","article-title":"The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram","volume":"99","author":"S\u00e1nchez","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib28","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.05.011_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","article-title":"Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed dose, 24-week study","volume":"23","author":"Stein","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.psy.0000146294.82810.9c","article-title":"Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis","volume":"66","author":"van Melle","year":"2004","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjmed.2011.12.002","article-title":"Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?","volume":"125","author":"Vieweg","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"17","author":"Wade","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.2011.368","article-title":"Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case\u2013time\u2013control study","volume":"92","author":"Weeke","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2013.05.011_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/15563650903585937","article-title":"Escitalopram causes fewer seizures in human overdose than citalopram","volume":"48","author":"Yilmaz","year":"2010","journal-title":"Clin.Toxicol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T12:15:53Z","timestamp":1563624953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0924977X13001739"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.05.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cardiovascular safety profile of escitalopram","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}